摘要
目的:单中心研究观察阿魏酸钠治疗2型糖尿病肾病Ⅳ期患者的效果。方法:160例2型糖尿病肾病Ⅳ期患者随机分为阿魏酸钠治疗组(以下称治疗组)和对照组。对照组予以控制血糖、降血脂等治疗,同时予以奥美沙坦40mg/d。治疗组在对照组治疗的基础上加用阿魏酸钠注射液300mg/d×30d,静脉滴注。比较两组患者治疗前后24h尿白蛋白定量(24hUAlb);血尿素氮(BUN)、血肌酐(Scr);血内皮素-1(ET-1)、转化生长因子(TGF-β1);尿视黄醇结合蛋白(RBP)、尿β2微球蛋白(β2-MG)的变化。结果:与治疗前比较,治疗组和对照组多项指标均明显好转;两组间比较差异有统计学意义(P<0.05),且治疗组效果更明显。结论:对于2型糖尿病肾脏病Ⅳ期患者,阿魏酸钠联合奥美沙坦可以明显减少2型糖尿病肾病Ⅳ期患者尿蛋白,保护肾功能,延缓纤维化的进程。
To investigate the protective effects of combination of sodium ferulate and olmesartan on the IV Stage of type 2 diabetic nephropathy. Methods：One hundred and sixty patients with type 2 diabetic nephropathy in phase IVwere enrolled and randomly divided into the control group（ controlling the blood glucose, reducing blood lipids, meanwhile reducing the blood pres sure and proteinuria with olmesartan 40 rag/d） and the treatment group（add Sodium Ferulate 300 mg; d^-1 for 30 days）. The treat ment lasted for 30 days, and the levels of all parameters asserum ET - 1, serum creatinine,BUN, serum TG,TC, 24 hours quantity for urinary albumin, urinary RBP, 132 - MG were measured before and after the therapy. Results：The serum Creatinine,BUN,ET - 1, TGF - 131,24 h UALB ; urinary132 - MG,urinaryRBP in both groups were improved, and there was statistical difference between these two groups（P 〈0.05）. The levels of all parameters of renal tubular function, as urinary RBP, 132 - MG, declined in the treatment group. Compared with the control group, there were significant statistical differences （P 〈 0.05 ）. Conclusion：The sodium ferulate on phase IV Of type 2 diabetic nephropathy has significant protective effects for reducing proteinuria, delaying the process of renal failure and fibrosis; however, more evidences will be needed.
出处
《中国中西医结合肾病杂志》
2013年第8期696-698,共3页
Chinese Journal of Integrated Traditional and Western Nephrology
基金
国家自然科学基金资助项目(No.81273950)
关键词
2
型糖尿病
肾病奥美沙坦
阿魏酸钠
Type 2 diabetic nephropathy Olmesartan Sodium ferulate
